Empagliflozin Improves Outcomes in Patients With Heart Failure and Preserved Ejection Fraction Irrespective of Age
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Empagliflozin Improves Outcomes in Patients With Heart Failure and Preserved Ejection Fraction Irrespective of Age
Authors
Keywords
-
Journal
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Volume 80, Issue 1, Pages 1-18
Publisher
Elsevier BV
Online
2022-06-28
DOI
10.1016/j.jacc.2022.04.040
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Angiotensin II-induced upregulation of SGLT1 and 2 contributes to human microparticle‐stimulated endothelial senescence and dysfunction: protective effect of gliflozins
- (2021) Sin-Hee Park et al. Cardiovascular Diabetology
- SGLT2 inhibitors as calorie restriction-mimetics: insights on longevity pathways and age-related diseases
- (2021) Caroline W S Hoong et al. ENDOCRINOLOGY
- SGLT2 inhibition reduces cellular senescence in the diabetic kidney by promoting ketone body‐induced NRF2 activation
- (2021) Mi Na Kim et al. DIABETES OBESITY & METABOLISM
- 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
- (2021) Theresa A McDonagh et al. EUROPEAN HEART JOURNAL
- Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood Pressure
- (2021) Michael Böhm et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Empagliflozin in Heart Failure with a Preserved Ejection Fraction
- (2021) Stefan D. Anker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial
- (2021) Javed Butler et al. CIRCULATION
- Therapeutic approaches in heart failure with preserved ejection fraction: past, present, and future
- (2020) Jan Wintrich et al. Clinical Research in Cardiology
- Longevity genes, cardiac ageing, and the pathogenesis of cardiomyopathy: implications for understanding the effects of current and future treatments for heart failure
- (2020) Milton Packer EUROPEAN HEART JOURNAL
- Minimal clinically important difference in quality of life scores for patients with heart failure and reduced ejection fraction
- (2020) Javed Butler et al. EUROPEAN JOURNAL OF HEART FAILURE
- Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights from the EMPEROR-Reduced Trial
- (2020) Faiez Zannad et al. CIRCULATION
- Empagliflozin reduces the senescence of cardiac stromal cells and improves cardiac function in a murine model of diabetes
- (2020) Rosalinda Madonna et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
- (2020) Milton Packer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Baseline Characteristics of Patients with Heart Failure with Preserved Ejection Fraction in the EMPEROR‐Preserved Trial
- (2020) Stefan D. Anker et al. EUROPEAN JOURNAL OF HEART FAILURE
- Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial
- (2019) David Fitchett et al. CIRCULATION
- Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus
- (2019) Eri T. Kato et al. CIRCULATION
- Age-dependent differences in clinical phenotype and prognosis in heart failure with mid-range ejection compared with heart failure with reduced or preserved ejection fraction
- (2019) Xiaojing Chen et al. Clinical Research in Cardiology
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
- (2019) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF
- (2019) Felipe A. Martinez et al. CIRCULATION
- Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction
- (2019) Jasper Tromp et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
- (2018) Thomas A Zelniker et al. LANCET
- Effect of age and sex on efficacy and tolerability of β blockers in patients with heart failure with reduced ejection fraction: individual patient data meta-analysis
- (2016) Dipak Kotecha et al. BMJ-British Medical Journal
- Effect of age and sex on efficacy and tolerability of β blockers in patients with heart failure with reduced ejection fraction: individual patient data meta-analysis
- (2016) Dipak Kotecha et al. BMJ-British Medical Journal
- Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF
- (2015) Pardeep S. Jhund et al. EUROPEAN HEART JOURNAL
- Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study
- (2013) Luigi Tavazzi et al. EUROPEAN JOURNAL OF HEART FAILURE
- Epidemiology and clinical course of heart failure with preserved ejection fraction
- (2010) Carolyn S.P. Lam et al. EUROPEAN JOURNAL OF HEART FAILURE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started